NLRP3 and familial dilated cardiomyopathy: In parallel, pharmacologic strategies are being developed to reduce myocardial fibrosis (e.g., NLRP3 inflammasome inhibitors), stabilize sarcomeric proteins (e.g., omecamtiv mecarbil, mavacamten), or modulate calcium homeostasis (e.g., L-type calcium channel blockers in arrhythmogenic forms of DCM) [146,147,148], with potential application in arrhythmogenic forms of DCM [10].